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ARTICLE
Preoperative predictors of pathological tumour stage and prognosis may be
used when selecting candidates for intensified treatment in upper tract
urothelial carcinoma
Bjarte Almåsa , Stein Øverbyb, Ole J. Halvorsenc,d, Lars A. R. Reisætere, Birgitte Carlsenf and
Christian Beislanda,c
aDepartment of Urology, Haukeland University Hospital, Bergen, Norway; bDepartment of Urology, Vestfold Hospital Trust, Tønsberg,
Norway; cDepartment of Clinical Medicine, University of Bergen, Bergen, Norway; dDepartment of Clinical Medicine, Section for Pathology,
Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway; eDepartment of Radiology, Haukeland University Hospital,
Bergen, Norway; fDepartment of Pathology, Vestfold Hospital Trust, Tønsberg, Norway
ABSTRACT
Purpose: Intensified treatment such as extended lymph node dissection (LND) and/or perioperative
chemotherapy in addition to radical nephroureterectomy (RNU) has been suggested for high-risk cases
of upper tract urothelial carcinoma (UTUC). We aimed to identify preoperative predictors of tumour
stage and prognosis in the diagnostic work-up before RNU. Further to evaluate if our findings could
be used in selecting patients for intensified treatment.
Patients and methods: A total of 179 patients treated with RNU for UTUC at Haukeland University
Hospital (HUS) and Vestfold Hospital Trust (VHT) during 2005–2017 were included in this retrospective
study. All relevant preoperative variables regarding the patient, the CT and the ureteroscopy (URS)
were registered and analysed regarding their ability to predict non-organ confined disease (NOCD,
pT3þ and/or Nþ) at final pathology after RNU. The prognosis was assessed calculating survival for the
cohort and stratified by preoperative variables.
Results: Local invasion and pathological lymph nodes at CT predicted NOCD in uni and multivariate
regression analyses (OR 3.36, p¼.004 and OR 6.21, p¼.03, respectively). Reactive oedema surrounding
the tumour (OR 2.55, p¼.02), tumour size (4.8 vs. 3.9 cm, p¼.006) and high-grade tumour at URS
biopsy (OR 3.59, p¼.04) predicted NOCD at univariate regression analyses. The 5-year CSS and OS for
the entire cohort was 79% and 60%. ECOG, local invasion, pathological lymph nodes and reactive
oedema surrounding the tumour at CT predicted CSS.
Conclusions: Several variables at the CT predicted both stage and survival. Local invasion at CT seems
the most promising feature for selecting patients for intensified treatment.
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Urothelial carcinoma in the upper urinary tract (UTUC) is
referred to constitute 5–10% of all urothelial carcinomas [1].
UTUC is an aggressive disease and at diagnosis about 40% of
the tumours are non-organ confined. The 5-year cancer-
specific survival (CSS) in these cases is below 50% [2,3]. The
standard treatment of invasive UTUC is a radical nephroureter-
ectomy (RNU) with complete excision of the ipsilateral bladder
cuff. Due to the high mortality of the disease, intensified treat-
ment including chemotherapy as neo-adjuvant or adjuvant
treatment or extended lymph node dissection (LND) have
been suggested for high-risk patients [4–7]. Due to the lack of
accurate staging tools of the disease preoperatively, it can be
challenging to identify the right indication for intensified treat-
ment. Current EAU-guidelines recommend computed tomog-
raphy (CT) urography as standard in diagnosis and
preoperative staging of UTUC. A ureteroscopy (URS) is recom-
mended if imaging and cytology are not sufficient for the
diagnosis and/or risk-stratification of the tumour [8].
The aim of this study was to analyse available preopera-
tive factors regarding their ability to predict histopathological
tumour stage and subsequent prognosis after RNU for UTUC
in a contemporary cohort in Norway. We further sought to
evaluate if our findings could be used in the selection of
patients for intensified treatment.
Material and method
Patient selection
After obtaining approval from the Regional ethics committee
(reference no. 2017/854), the medical records of 209 patients
treated with a RNU between 2005 and 2017 for suspected
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UTUC at Haukeland University Hospital (HUS, n¼ 130) and
the Vestfold Hospital Trust (VHT, n¼ 79), were retrospectively
examined. A total of 30 patients were excluded due to con-
comitant bladder cancer with cystectomy in the same pro-
cedure as RNU (n¼ 9), non-urothelial cancer (n¼ 15, most of
them renal cell carcinoma) or no malignancy detected at the
final histopathological specimen after RNU (n¼ 6), leaving
179 patients for inclusion in the study.
Diagnostic work-up, treatment and follow-up
Standard preoperative assessment was a CT scan with con-
trast unless contraindicated. If there was doubt about the
diagnosis or the patient was a potential candidate for kidney
sparing treatment, a URS was performed. Endoscopic treat-
ment or segmental ureter resection was considered among
patients with low-stage UTUC of limited size clinically. The
indication for RNU was a high-grade or invasive UTUC unless
contraindicated due to comorbidity and/or high age. The
RNU was performed as an open or laparoscopic procedure
with complete excision of the bladder cuff. Chemotherapy
was not standard treatment and neo-adjuvant chemotherapy
was given to only one patient prior to RNU. LND was per-
formed at the discretion of the surgeon. Follow-up included
cystoscopy every three months for the first two years. A CT
scan was commonly performed after 12 months or whenever
the patient presented with symptoms suggestive of meta-
static disease. Later follow-up was individualized.
Patient factors
Patient age, sex, comorbidities, kidney function, presenting
symptoms and smoking status were registered together with
the presence of prior bladder cancer or prior endoscopic
treatment for UTUC.
Radiological analysis
A total of 176 (98%) of the patients were examined with a
CT scan, 159 (90%) of these with a contrast-enhanced CT, 17
patients were examined with a CT without contrast due to
kidney failure. One patient was examined with magnetic res-
onance imaging only, one with a conventional intravenous
urography only and one lacked preoperative radiological
examination of the upper urinary tract. All CT scans were re-
evaluated by a uro-radiologist (LAR) together with a urologist
(BA) and assessed regarding tumour size, location, contrast
enhancement, the presence of hydronephrosis, pathological
lymph nodes, reactive oedema surrounding the tumour and
local invasion into renal parenchyma, the renal pelvis or peri-
ureteric tissue. Each variable was considered by the radiolo-
gist in each patient to assess if a reliable measurement could
be made in that particular case. If for example reliable meas-
urements regarding tumour size and/or contrast enhance-
ment could not be made in one particular case, the variable
was recorded as missing in the dataset. This results in a dif-
ferent number of patients available for analysis for each vari-
able, as demonstrated in Table 3.
Ureteroscopy with biopsy and cytology evaluation
A total of 95 (53%) patients were examined with a preopera-
tive URS with biopsy before RNU. A total of 60 patients were
examined with a preoperative urinary cytology and 43 of
these had cytology taken during URS. The ability of the
biopsy to confirm UTUC diagnosis was registered together
with information about biopsy tumour grade and stage.
Histopathological examination
Data regarding tumour location, stage and grade were gath-
ered from the pathology reports at the respective institu-
tions. Tumours were graded according to the two-tiered
WHO 2004 classification [9] and staged according to TNM
2017 classification [10]. All specimens originally not concur-
ring with these two classifications were re-examined and
reclassified by uropathologists (OJH and BC).
Statistical analysis; prediction of prognosis and
tumour stage
Continuous and categorical variables were analysed using a
Student’s t-test and a chi-square test, respectively. Survival
estimates were calculated using the Kaplan–Meier method,
and a log-rank test was used to compare groups. The esti-
mated 5- and 10 year overall survival (OS) and cancer (UTUC)
specific survival (CSS) were calculated for the entire cohort.
Furthermore, multivariate cox regression analyses including
both patient features and final histopathology were per-
formed to evaluate independent predictors of all-cause and
cancer-specific mortality. The purpose of these analyses was
to evaluate if survival and prognostic factors in the present
cohort were similar to other larger published patient series
on operated UTUC patients.
Univariate prediction of prognosis according to pure pre-
operative variables was then assessed by Kaplan–Meier esti-
mates. Recurrence and metastasis after RNU for UTUC will in
most cases result in death from UTUC, thus 5-year CSS was
chosen as the primary outcome parameter. For prediction of
tumour stage at final histopathological examination after
RNU, all candidate variables regarding patient features, CT
and ureteroscopic findings were analysed using univariate
and multivariate logistic regression analysis to assess their
abilities to predict non-organ confined disease (NOCD).
NOCD was defined as pT3 or more (invasion into the renal
parenchyma, renal pelvis or periureteral tissue) and/or Nþ
(lymph node positive) at final pathology.
Both the cox and logistic multivariate regression analyses
were performed in a backward manner. To pre-select
included candidate variables a cut off of p<.2 in univariate
analyses were chosen. For all analyses, a p value less than
.05 were considered statistically significant. All analyses were
performed by use of SPSS version 26.0 (IBM, Armonk, NY).
Results
The patient demographics and tumour characteristics are
presented in Table 1.
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Prediction of survival
The 5- and 10 year CSS of the whole cohort was 79% and
75%, respectively. The 5- and 10-year OS was 60% and 35%,
respectively. Patients with OCD had a higher CSS (93% vs.
55%, p<.001) and OS (71% vs. 42%, p<.001) compared to
patients with NOCD (Supplementary Figures 1 and 2). Mean
(median) follow-up time in patients alive without recurrence
was 58 (47) months. In a multivariate cox regression analysis,
pathological tumour stage and ECOG were significant predic-
tors of all-cause mortality. Pathological tumour stage
predicted UTUC specific mortality (Supplementary Tables 1
and 2).
The presence of local invasion (64% vs. 86%, p¼ 0.002),
pathological lymph nodes (41% vs. 83%, p<.001) and fatty
tissue reaction surrounding the tumour (58% vs. 84%,
p¼.001) at CT predicted CSS in the present material.
Regarding patient factors, ECOG 0 predicted improved CSS
compared to ECOG  1 (85% vs. 70%, p¼.03). No other fea-
tures regarding the patient, radiological examinations or ure-
terrenoscopic variables predicted CSS in this study.
Prediction of tumour stage
Patient features
The results of the univariate regression analyses regarding
patient factors ability to predict NOCD are shown in Table 2.
No patient factors were shown to be predictors of NOCD at
final pathology in this study.
Radiological variables
The results of the univariate regression analyses regarding CT
variables are shown in Table 3. Non-organ confined tumours
were larger than organ-confined tumours (4.8 cm vs. 3.9 cm,
p¼.006). The presence of reactive oedema in the fatty tissue
surrounding the tumour predicted NOCD (OR 2.55, p¼.016).
This was particularly true for tumours in the ureter with an
OR of 8.0 for those tumours (p¼.002). The presence of patho-
logical lymph nodes and local invasion on CT predicted
NOCD (OR 14.5, p¼.001 and 5.31, p<.001, respectively). The
sensitivity and specificity of local invasion at CT to predict
NOCD was 49% and 85%, respectively. The sensitivity and
specificity of pathological lymph nodes CT to predict NOCD
was 22% and 98%, respectively. Hydronephrosis was present
in 114 of 173 patients (66%). Contrast enhancement and the
presence of hydronephrosis did not predict NOCD in this
patient material.
Ureterrenoscopic variables
The results of the univariate regression analyses regarding
the ureterrenoscopic variables are described in Table 4. A
diagnostic URS with biopsy was performed in 95 patients. In
66 (69%) of the patients, the biopsy could be used to con-
firm UTUC diagnosis, and in 57 (60%) the biopsy material
was sufficient to determine tumour grade. Presence of high-
grade tumour at biopsy predicted NOCD (OR 3.59, p¼.04).
The sensitivity and specificity of high-grade biopsy to predict
NOCD was 63% and 68%, respectively. Out of 34 low-grade
tumours at biopsy, 12 (35%) were upgraded to high-grade at
final pathology after RNU. No high-grade tumours were
downgraded. The tumour stage at biopsy did not predict
NOCD in the present material. A cytology sample was taken
in 60 patients, 43 of these taken during URS. Malignant cells
were detected among 37 (62%) of these. Malignant cells at
cytology did not predict NOCD in the present material.
Table 1. Patient and tumour characteristics.
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Current smoker 63 35
Previous smoker 48 27

















aEastern Cooperative oncology group.
btumour grade according to WHO/ISUP classification 2004.
cpT3 or more and/or Nþ disease at final pathology after nephroureterectomy.
Table 2. Univariate odds ratios for non-organ confined disease according to
patient risk variable.
Variable ORb 95 % CIa p Value
Age 0.99 0.96–1.02 .5
Female vs. male 1.07 0.56–2.02 .8
Symptoms
Local vs. none 1.26 0.63–2.53 .5
ECOGc
1 or more vs. 0 1.03 0.56–1.89 .9
Smoking status
Never smoking vs. history of smoking 1.68 0.90–3.11 .1
Previous bladder cancer 0.93 0.45–1.90 .8
Previous endoscopic treatment 0.51 0.18–1.47 .2
Tumour location
Ureter vs. kidney pelvis 0.71 0.37–1.34 .3




cEastern cooperative oncology group.
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Multivariate analyses
All variables with a predictive value for NOCD with a p-value
<0.2 (smoking status, presence of hydronephrosis, fatty tis-
sue reactive oedema or pathological lymph nodes together
with tumour size and local invasion at CT) were entered into
a multivariate logistic regression analysis. The results from
these analyses are shown in Table 5. Pathological lymph
nodes and local invasion on CT remained significant predic-
tors of NOCD (6.21, p¼.03 and 3.36, p¼.004, respectively).
Discussion
In this study, several variables from the CT images and
biopsy tumour grade were identified as preoperative predic-
tors for NOCD. With the exception of biopsy tumour grade
and tumour size, these factors also predicted survival.
One of the unanswered questions regarding the preopera-
tive diagnostic procedures before RNU for UTUC is the role
of the diagnostic URS. In the current EAU-guidelines, a URS is
recommended if imaging and cytology are not sufficient for
the diagnosis and/or risk-stratification of the tumour [8].
There is a role for the diagnostic URS in case the result of
the CT is unclear and further examinations to set the correct
diagnosis are necessary. Moreover, another indication is if the
patient is a potential candidate for nephron-sparing treat-
ment, such as a segmental ureter resection or endoscopic
laser tumour ablation. The evaluation of the diagnostic URS
in these settings was not among the aims of this paper, and
will not be discussed further here.
When it comes to the staging of UTUC, the role of the
diagnostic URS is much more unclear. Tumour grade is
regarded as a predictor of tumour stage at final pathology
[2]. However, the problem with tumour grade from biopsy is
that it is often not possible to get a biopsy at all at the pro-
cedure, and in case a low-grade biopsy is found, it is fre-
quently upgraded to high-grade at final pathology. In the
present paper, the biopsy could confirm UTUC diagnosis
only in 69% of the cases. This might seem like a low rate of
histological verification, but is in line with the findings in a
prospective study evaluating URS biopsies. Breda et al. found
that a histological evaluation was possible in 78% of the
biopsies, with complete histopathological assessment only
among 46%. [11]. One could of course turn this around and
say that histological confirmation from URS biopsy is possible
in a majority of the cases, and such verification is a require-
ment for the oncologists before considering neo-adjuvant
chemotherapy. However, histological verification can also be
achieved through cytology at cystoscopy which is mandatory
before RNU. In the present cohort, the sensitivity of cytology
to verify UTUC was 62%, not very different from the sensitiv-
ity of 69% from the URS biopsy. Another aspect of the URS
biopsy was that 35% of the low-grade biopsies were
upgraded to high-grade at final pathology. Such upgrading
is a known phenomenon. A meta-analysis on the topic analy-
sing more than 2000 URS biopsies from 23 studies concluded
that the pooled upgrading rate from low- to high-grade
tumours was at 34% [12], and thus in line with our results.
Table 4. Results of the analyses made from the ureterenoscopic variables
regarding determination of biopsy tumour grade and prediction of non-organ
confined disease at final pathology after nephroureterectomy.
Variable n % ORa CIb p Value
Diagnostic URS performed 95 100
Biopsy method
Forceps only 66 70
Basket only 14 15
Both forceps and basket 13 14
N/A 2 2
Biopsy verified UTUC 66 69
Biopsy WHO grade 2004 57 60
High grade 23 3.59 1.07–12.0 .04
Low grade 34
Low-grade tumours at URS 34
Remain low-grade at final
pathology
22 65c
Upgraded to high-grade at
final pathology
12 35c
Biopsy tumour stage 60 63
Ta/Tx 50
T1 or T2 10 3.55 0.87–14.5 .08
Cytology taken 60 63
Malignant cells 37 1.84 0.55–6.14 .3
aOdds ratios.
bConfidence interval.
cPercentage of low-grade tumours at biopsy either verified as low-grade
tumours or upgraded to high-grade tumours at final pathology after radical
nephroureterectomy.
Table 3. Univariate analyses for prediction of non-organ confined disease according to variables at CT scan.
Variable n (%)a
Continuous variables All NOCD 95% CIb OCD 95% CIc p Value
Tumour size (cm) 163 (91) 4.2 4.8 4.2–5.3 3.9 3.6–4.3 .006d
Contrast enhancement (HU) 111(62) 38 36 32–40 39 35–43 .4a
Categorical variables ORe 95% CIb p
Fatty tissue oedema (all) 164 (92) 2.55 1.19–5.46 .016b
Fatty tissue oedema (ureter only) 55 (31) 8.0 2.13–30.1 .002b
Hydronephrosis 173 (97) 0.62 0.32–1.17 .14b
Pathological lymph nodes 173 (97) 14.5 3.19–66.4 .001b
Local invasion 162 (91) 5.31 2.53–11.1 <.001b
Tumour size, oedema in the fatty tissue surrounding the tumour, the presence of pathological lymph nodes and local invasion into renal,
peripelvic or periureteric tissue were shown to be significant predictors of non-organ confined disease at final pathology after
nephroureterectomy.
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In spite of the demonstrated limitations regarding the
diagnostic URS, biopsy tumour grade was still a significant
predictor of NOCD at univariate analyses in the present
material, and further analyses were made to assess potential
clinical benefit. The sensitivity and specificity of high-grade
tumour at biopsy to predict NOCD were 63% and 68%,
respectively. We think that the accuracies of these predic-
tions are too low to be clinically useful. Furthermore, there is
also the aspect that URS requires time and resources, and
thus delays definite treatment. Finally, in two meta-analyses,
an increased risk of post-RNU bladder recurrence has been
demonstrated among patients examined with URS [13,14].
To conclude, URS as a diagnostic measure among patients
where a decision for RNU has already been made has consid-
erable limitations, and will only rarely influence the decision
about intensified treatment. It causes curative treatment
delay and an increased risk of bladder recurrence after RNU.
We argue that a preoperative URS should be spared for cases
where the diagnosis is uncertain or when nephron-sparing
treatment might be an option.
How can our findings be used in a clinical practice? If a
URS is omitted in the preoperative diagnostic work-up, the
clinician is left with the findings (a) in the CT scan and (b) at
cystoscopy visit when deciding on potential intensified treat-
ment. There is emerging evidence of the efficacy of peri-
operative chemotherapy, but selecting the appropriate
patients for this is challenging. Indeed, in Norway, different
approaches to perioperative chemotherapy at different hos-
pitals exist. The POUT study has recently demonstrated the
efficacy of adjuvant chemotherapy in case of muscle-invasive
disease [4], and one could argue that the best strategy is
simply to wait for final pathology and then decide whether
to give adjuvant chemotherapy or not. However, neo-adju-
vant chemotherapy in the treatment of UTUC has some
appealing advantages. Neo-adjuvant chemotherapy before
cystectomy for bladder cancer has demonstrated survival
benefit, and is standard treatment according to guidelines
[15]. Second and perhaps more importantly, a RNU will inev-
itably reduce the kidney function of the patient. We know
that this will make a significant proportion of the patients
ineligible for adjuvant chemotherapy due to reduced kidney
function postoperatively. On the other hand, giving neo-
adjuvant to all chemo-eligible patients undergoing RNU will
inevitably result in giving a toxic and potentially lethal treat-
ment to a large group of patients with non-muscle invasive
disease. In the present material, the proportion of patients
with Ta and T1 disease was 47%. The proportion of patients
with organ-confined disease was 62%. We think that giving
neo-adjuvant treatment to patients with non-muscle invasive
disease would result in unacceptable side effects to a patient
group where the potential benefit of the treatment is
highly debatable.
So how can we select the appropriate patients for neo-
adjuvant chemotherapy? Both pathological lymph nodes and
fatty tissue oedema predicted NOCD in the present cohort.
However pathological lymph nodes had a very low sensitivity
of 22% in predicting NOCD and would result in missing out
many potential candidates for neo-adjuvant chemotherapy.
Fatty tissue reaction surrounding the tumour also demon-
strated predictive ability, but this is a feature that to our
knowledge has not been demonstrated as a predictor for
tumour stage after RNU before. Its predictive abilities should
be confirmed in further studies before it is taken into stand-
ard clinical practice.
The presence of local invasion on CT seems a more prom-
ising feature to use in patient selection for neo-adjuvant
chemotherapy. It was found to be a significant predictor of
NOCD and survival in the present cohort. The predictive abil-
ity of local invasion at CT has been described by other
authors. In a diagnostic model presented by Favaretto et al.,
local invasion at CT was found to predict NOCD and was
used as a part of their presented diagnostic model [16]. A
recently published study reported a sensitivity and specificity
of 75% and 83% correspondingly using CT to detect
advanced stage (T3/T4) UTUC [17].
Local invasion on CT in this study showed a relatively low
sensitivity of 48% but a corresponding high specificity of
85% in predicting NOCD. A sensitivity of 48% might seem
unacceptably low, but this sensitivity as a cut off is the same
as suggested in a recently published model by Petros et al.
The authors of that study generated a predictive model that
included findings at CT, URS and blood samples to reach a
sensitivity of 49% and specificity of 95% in predicting NOCD
[18]. The higher specificity demonstrated in their model is
beneficiary, but comes at the cost of a highly complicated
model using parameters from URS and blood samples in
addition to findings at the CT in a nomogram. In our opin-
ion, the complexity of the model makes it less useful in day
to day clinical practice.
By using the accuracy from this study, invasion at CT as a
guide for who could benefit from neo-adjuvant, would result
in only half of the patients with NOCD receiving chemo as a
Table 5. Multivariate regression analyses for prediction of NOCD at final specimen according to risk variables.
Variable
ORa CIb p Value
Tumour size at CT 0.94 0.77–1.16 .6
History of smoking vs. never smokers 1.53 0.72–3.24 .3
Hydronephrosis at CT 0.59 0.28–1.23 .2
Reactive oedema in fatty tissue surrounding tumour at CT 0.62 0.26–1.50 .3
Pathological lymph nodes at CT 6.21 1.21–31.3 .03
Local invasion into renal parenchyma or periureteric tissue 3.36 1.47–7.69 .004
Variables with a p value of <.2 were taken into the analysis. Pathological lymph nodes and local invasion into renal par-
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neoadjuvant. However, few patients with non-muscle inva-
sive disease would be ‘overtreated’ with chemotherapy. The
patients with muscle-invasive disease that did not receive
neo-adjuvant chemotherapy could be good candidates for
adjuvant chemotherapy. If the kidney function was still
acceptable (GFR > 55), Cisplatin-based regimens would be
preferred. If not, Carboplatin based regimens could be an
option. Both these regimens of adjuvant chemotherapy were
included and shown to be beneficial in the POUT study.
High-quality randomized studies comparing neo-adjuvant
Figure 1. Demonstrating a proposed flowchart that can be used in the selection of patients for perioperative chemotherapy and/or extended LND in adjunct to
radical nephroureterectomy for upper tract urothelial carcinoma. UTUC: upper tract urothelial carcinoma. RNU: Radical nephroureterectomy. LND: Lymph node dis-
section; NOCD: non-organ confined disease; OCD: organ-confined disease; MID: muscle-invasive disease; GFR: glomerular filtration rate.
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with adjuvant chemotherapy in the treatment of UTUC are
urgently needed. Pending evidence from such high-quality
studies, we suggest that this very simple and readily avail-
able feature can be used as a guide for selecting patients for
either neo-adjuvant or adjuvant chemotherapy. Its use is
demonstrated in a proposed flowchart (Figure 1).
The same approach can be used when selecting patients
for extended LND. Current EAU guidelines recommend that a
template-based LND should be performed during RNU [8]. In
case pathological but resectable lymph nodes are present on
the preoperative CT, an LND should be performed. However,
the presence of lymph nodes metastasis is strongly depend-
ent on tumour stage, and an LND appears to be unnecessary
in Ta/T1 tumours [19]. In case the CT is negative for patho-
logical lymph nodes but local invasion is present, an LND
could be performed with an indication similar to that of neo-
adjuvant chemotherapy (Figure 1).
The inclusion of survival analyses presented in this study
serve two purposes. First, the 5-year DSS of 79% in this study
is comparable to the DSS presented in larger cohorts [20,21].
This suggests that our cohort is a representative sample of
UTUC cohorts in general, and could increase the generaliz-
ability of our findings. Second, the same predictors of
tumour stage at CT also predicted survival in our study. This
was as expected, but these findings further underscore the
importance of the predictors we discovered both regarding
stage and survival.
Strengths and weaknesses
The strengths of this article include using patients from two
larger centres in Norway to allow enough patients to make
robust analyses of staging and survival. However, increasing
the number of patients by collaborating with additional
centres would have increased the generalizability of our find-
ings further. All CT scans were re-evaluated by a uro-radiolo-
gist and all re-evaluations of histopathological specimens
were performed by uro-pathologists to increase data quality
as much as possible. The weakness of the study is its retro-
spective study design, with the inherent weaknesses associ-
ated with this study design.
Conclusion
Several features in the preoperative diagnostics before RNU
for UTUC were shown to predict tumour stage and survival
in this study. Of these, local invasion on CT seems to be the
most promising feature when selecting the appropriate
patients for intensified treatment for UTUC. The role of the
diagnostic URS in the staging of UTUC seems limited. The
preoperative staging of UTUC before RNU remains challeng-
ing, and further studies on the topic are warranted.
Disclosure statement
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